US approves drug against Alzheimer’s disease – Kommersant
[ad_1]
The US Federal Food and Drug Administration (FDA) on Thursday approved use of the first drug that slows down the development of Alzheimer’s disease. This is the drug Leqembi, developed by the Japanese pharmaceutical company Eisai and the American Biogen. At the same time, the FDA required that information be placed on Leqembi packages that a side effect of using drugs of this kind could be cerebral edema.
Leqembi is the first approved drug that not only treats the symptoms of Alzheimer’s disease, but also slows down the process of its development and cognitive decline. Clinical trials have shown that taking Leqembi slowed the progression of the disease by 27% in patients with early stages of the disease. The drug had already received accelerated FDA approval in January, but full approval was needed before the drug could be covered by health insurance.
In May, another pharmaceutical company, Eli Lilly, reported about successful trials of his own experimental drug that slows down cognitive decline in Alzheimer’s disease.
[ad_2]
Source link
